Sign inCreate account

Report workspace tools

NCT02612909COMPLETEDanonymous

A Phase 2/3 Double Blinded, Randomized, Placebo-controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC

Sponsor

Source record

Institute of Vaccines and Medical Biologicals, Vietnam

Phase

Source record

PHASE2

Modality

AI-normalized

vaccine

Target

AI-normalized

IVACFLU-A/H5N1 vaccine, Placebo

Indication / condition

AI-normalized

Avian Influenza

Intervention

Source record

IVACFLU-A/H5N1 vaccine, Placebo

Source & freshness

Source record

NCT ID

NCT02612909

Original source

ClinicalTrials.gov

Source last updated

May 21, 2019

Ingested at

Jun 08, 2026

Internal sync

Jun 08, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02612909

Title

A Phase 2/3 Double Blinded, Randomized, Placebo-controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC

Sponsor

Institute of Vaccines and Medical Biologicals, Vietnam

Status

COMPLETED

Phase

PHASE2

Condition raw

Avian Influenza

Condition normalized

Avian Influenza

Modality raw

vaccine

Modality normalized

vaccine

Target raw

IVACFLU-A/H5N1 vaccine, Placebo

Target normalized

IVACFLU-A/H5N1 vaccine, Placebo

Interventions

IVACFLU-A/H5N1 vaccine, Placebo

Public preview

Source record

The study hypothesis was that two 0.5 mL doses of whole virion monovalent A/H5N1 influenza vaccine (IVACFLU-A/H5N1) adjuvanted with alum would be safe and well tolerated in healthy adults, and that at least one of the two doses tested would be immunogenic in 60% or more of the subjects tested.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2/3 Double Blinded, Randomized, Placebo-controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02612909

Status

COMPLETED

Phase

PHASE2

Sponsor

Institute of Vaccines and Medical Biologicals, Vietnam

Executive brief

Investment-Ready Snapshot

The study hypothesis was that two 0.5 mL doses of whole virion monovalent A/H5N1 influenza vaccine (IVACFLU-A/H5N1) adjuvanted with alum would be safe and well tolerated in healthy adults, and that at least one of the two doses tested would be immunogenic in 60% or more of the subjects tested.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 21, 2019
Internal syncJun 08, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02612909

Indication

Avian Influenza

Modality

vaccine

Target

IVACFLU-A/H5N1 vaccine, Placebo

Intervention

IVACFLU-A/H5N1 vaccine, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.